Last 7 days
3.1%
Last 30 days
-15.3%
Last 90 days
-21.7%
Trailing 12 Months
-30.6%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AAPL | 2.5T | 387.5B | -0.56% | -0.91% | 25.94 | 6.37 | 2.44% | -5.35% |
MSFT | 2.1T | 204.1B | -1.92% | -6.89% | 30.5 | 10.08 | 10.38% | -5.25% |
GOOG | 1.3T | 282.8B | 1.63% | -25.54% | 21.65 | 4.59 | 9.78% | -21.12% |
AMZN | 1.0T | 514.0B | -3.36% | -34.72% | -376.42 | 1.99 | 9.40% | -108.16% |
MID-CAP | ||||||||
NYMT | 3.6B | 258.4M | 203.99% | 176.76% | -11.9 | 13.75 | 24.91% | -254.56% |
JBLU | 2.3B | 9.2B | -18.97% | -49.38% | -6.41 | 0.25 | 51.67% | -98.90% |
SMALL-CAP | ||||||||
PLAY | 1.7B | 1.7B | -22.36% | -14.62% | 13.72 | 0.97 | 61.79% | 371.82% |
TLRY | 1.6B | 602.5M | -17.77% | -52.80% | -2.74 | 2.63 | 18.18% | -18.59% |
BYND | 1.1B | 418.9M | 5.51% | -56.16% | -2.93 | 2.57 | -9.85% | -101.06% |
CGC | 991.7M | 478.9M | -11.35% | -65.42% | -0.32 | 2.07 | -31.50% | -634.70% |
MFA | 954.9M | 482.4M | -16.25% | -37.64% | -4.12 | 1.98 | 33.15% | -170.42% |
NKLA | 897.6M | 50.8M | -34.66% | -77.56% | -1.14 | 17.66 | 1229.98% | -13.59% |
GPRO | 788.4M | 1.1B | -10.56% | -33.33% | 27.33 | 0.72 | -5.82% | -92.23% |
INO | 281.8M | 10.3M | -24.84% | -63.38% | -1.01 | 27.46 | 478.23% | 7.85% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -1.6% | 38,627,000 | 39,240,000 | 38,701,000 | 34,360,000 | 29,750,000 |
Operating Expenses | 4.8% | 222,494,000 | 212,370,000 | 194,110,000 | 170,468,000 | 147,636,000 |
S&GA Expenses | 1.5% | 37,997,000 | 37,448,000 | 36,043,000 | 33,900,000 | 31,202,000 |
R&D Expenses | 5.5% | 184,497,000 | 174,922,000 | 158,067,000 | 136,568,000 | 116,434,000 |
EBITDA | -5.0% | -175,011,000 | -166,734,000 | -150,793,000 | - | - |
EBITDA Margin | -6.6% | -4.53 | -4.25 | -3.90 | - | - |
Earnings Before Taxes | -5.3% | -180,360,000 | -171,301,000 | -154,550,000 | -135,392,000 | -117,063,000 |
EBT Margin | -7.0% | -4.67 | -4.37 | -3.99 | - | - |
Net Income | -5.3% | -180,360,000 | -171,345,000 | -154,471,000 | -135,452,000 | -117,194,000 |
Net Income Margin | -6.9% | -4.67 | -4.37 | -3.99 | - | - |
Free Cahsflow | -5.4% | -172,051,000 | -163,304,000 | -145,450,000 | - | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -9.3% | 417 | 459 | 394 | 438 | 477 |
Current Assets | -10.3% | 318 | 355 | 307 | 280 | 311 |
Cash Equivalents | 35.6% | 64.00 | 48.00 | 42.00 | 79.00 | 81.00 |
Net PPE | 4.0% | 17.00 | 17.00 | 16.00 | 14.00 | 11.00 |
Liabilities | -3.2% | 113 | 117 | 128 | 132 | 134 |
Current Liabilities | 4.7% | 71.00 | 68.00 | 73.00 | 66.00 | 66.00 |
Shareholder's Equity | -11.3% | 304 | 343 | 267 | 306 | 342 |
Retained Earnings | -13.2% | -401 | -354 | -308 | -263 | -220 |
Additional Paid-In Capital | 1.2% | 709 | 701 | 579 | 571 | 564 |
Accumulated Depreciation | 6.3% | 17.00 | 16.00 | 15.00 | - | - |
Shares Outstanding | 0.1% | 47.00 | 47.00 | 45.00 | 45.00 | 45.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -4.6% | -159 | -152 | -136 | -135 | -84.36 |
Share Based Compensation | 14.0% | 28.00 | 25.00 | 22.00 | 19.00 | 16.00 |
Cashflow From Investing | 142.3% | 27.00 | -64.33 | -13.49 | -65.83 | -108 |
Cashflow From Financing | -0.5% | 117 | 118 | 4.00 | 154 | 154 |
92.8%
89.2%
70.5%
Y-axis is the maximum loss one would have experienced if Nurix Therapeutics was unfortunately bought at previous high price.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | sold off | -100 | -147,000 | - | -% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 575 | 4,000 | 4,000 | -% |
2023-02-28 | Voya Investment Management LLC | unchanged | - | -37,020 | 197,980 | -% |
2023-02-24 | NATIXIS | new | - | 82,581 | 82,581 | -% |
2023-02-15 | LAZARD ASSET MANAGEMENT LLC | new | - | 11,000 | 11,000 | -% |
2023-02-15 | Jasper Ridge Partners, L.P. | unchanged | - | -196,093 | 1,050,910 | 0.06% |
2023-02-15 | Metropolitan Life Insurance Co/NY | unchanged | - | -5,321 | 29,679 | -% |
2023-02-15 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | added | 12.01 | -55,000 | 919,000 | -% |
2023-02-15 | MetLife Investment Management, LLC | unchanged | - | -47,298 | 255,702 | -% |
2023-02-15 | NOMURA HOLDINGS INC | added | 19.52 | 17,000 | 3,118,000 | 0.01% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 24, 2023 | deep track capital, lp | 5.75% | 2,717,171 | SC 13G | |
Feb 14, 2023 | third rock ventures iii, l.p. | 0% | 0 | SC 13G/A | |
Feb 14, 2023 | deep track capital, lp | 4.81% | 2,266,569 | SC 13G/A | |
Feb 14, 2023 | price t rowe associates inc /md/ | 6.9% | 3,253,736 | SC 13G/A | |
Feb 14, 2023 | redmile group, llc | 9.9% | 4,899,772 | SC 13G/A | |
Feb 14, 2023 | baker bros. advisors lp | 9.99% | 4,801,954 | SC 13G/A | |
Feb 08, 2023 | wasatch advisors inc | - | 0 | SC 13G | |
Jan 25, 2023 | blackrock inc. | 8.8% | 4,142,528 | SC 13G/A | |
Jun 10, 2022 | deep track capital, lp | 5.19% | 2,436,164 | SC 13G | |
Feb 14, 2022 | third rock ventures iii, l.p. | 5.4% | 2,422,549 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 13, 2023 | 8-K | Current Report | |
Feb 24, 2023 | SC 13G | Major Ownership Report | |
Feb 15, 2023 | 4 | Insider Trading | |
Feb 15, 2023 | 4 | Insider Trading | |
Feb 15, 2023 | 4 | Insider Trading | |
Feb 15, 2023 | 4 | Insider Trading | |
Feb 15, 2023 | 4 | Insider Trading | |
Feb 14, 2023 | SC 13G/A | Major Ownership Report | |
Feb 14, 2023 | SC 13G/A | Major Ownership Report | |
Feb 14, 2023 | SC 13G/A | Major Ownership Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-01-30 | Ring Christine | acquired | - | - | 1,924 | general counsel |
2023-01-30 | Ring Christine | sold | -9,989 | 11.7796 | -848 | general counsel |
2023-01-30 | van Houte Hans | sold | -10,884 | 11.7796 | -924 | chief financial officer |
2023-01-30 | van Houte Hans | acquired | - | - | 2,886 | chief financial officer |
2023-01-30 | Wolff Stefani | acquired | - | - | 962 | evp and coo |
2023-01-30 | Wolff Stefani | sold | -4,994 | 11.7796 | -424 | evp and coo |
2023-01-30 | Hansen Gwenn | acquired | - | - | 3,207 | chief scientific officer |
2023-01-30 | Hansen Gwenn | sold | -16,632 | 11.7796 | -1,412 | chief scientific officer |
2022-10-31 | Ring Christine | sold | -9,003 | 12.8805 | -699 | general counsel |
2022-10-31 | van Houte Hans | sold | -9,518 | 12.8805 | -739 | chief financial officer |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
May 31, 2022 | May 31, 2021 | May 31, 2022 | May 31, 2021 | |
Income Statement [Abstract] | ||||
Collaboration revenue | $ 11,432,000 | $ 7,091,000 | $ 21,053,000 | $ 12,102,000 |
Operating expenses: | ||||
Research and development | 47,493,000 | 25,994,000 | 90,630,000 | 48,997,000 |
General and administrative | 9,654,000 | 7,511,000 | 18,882,000 | 14,041,000 |
Total operating expenses | 57,147,000 | 33,505,000 | 109,512,000 | 63,038,000 |
Loss from operations | (45,715,000) | (26,414,000) | (88,459,000) | (50,936,000) |
Interest and other income, net | 314,000 | 171,000 | 525,000 | 489,000 |
Loss before income taxes | (45,401,000) | (26,243,000) | (87,934,000) | (50,447,000) |
Provision for income taxes | 0 | 139,000 | 0 | 210,000 |
Net loss | $ (45,401,000) | $ (26,382,000) | $ (87,934,000) | $ (50,657,000) |
Net loss per share, basic | $ (1.01) | $ (0.60) | $ (1.96) | $ (1.23) |
Weighted-average number of shares outstanding, basic | 44,898,409 | 43,804,066 | 44,797,235 | 41,318,281 |
Net loss per share, diluted | $ (1.01) | $ (0.60) | $ (1.96) | $ (1.23) |
Weighted-average number of shares outstanding, diluted | 44,898,409 | 43,804,066 | 44,797,235 | 41,318,281 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | May 31, 2022 | Nov. 30, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 41,533 | $ 80,506 |
Short-term investments | 255,746 | 215,214 |
Accounts receivable | 6,000 | |
Income tax receivable | 204 | |
Prepaid expenses and other current assets | 9,510 | 9,194 |
Total current assets | 306,789 | 311,118 |
Long-term investments | 51,538 | 137,189 |
Operating lease right-of-use assets | 15,418 | 14,005 |
Property and equipment, net | 15,507 | 11,340 |
Restricted cash | 901 | 286 |
Other assets | 4,157 | 2,833 |
Total assets | 394,310 | 476,771 |
Current liabilities: | ||
Accounts payable | 6,142 | 6,650 |
Accrued expenses and other current liabilities | 19,734 | 14,549 |
Operating lease liabilities, current | 5,470 | 3,847 |
Deferred revenue, current | 41,319 | 41,212 |
Total current liabilities | 72,665 | 66,258 |
Operating lease liabilities, net of current portion | 9,043 | 9,189 |
Deferred revenue, net of current portion | 45,863 | 59,022 |
Total liabilities | 127,571 | 134,469 |
Commitments and contingencies (Note 6) | ||
Stockholdersʼ equity: | ||
Preferred stock, $0.001 par value— 10,000,000 shares authorized as of May 31, 2022 and November 30, 2021; no shares issued and outstanding as of May 31, 2022 and November 30, 2021 | ||
Common stock, $0.001 par value— 500,000,000 shares authorized as of May 31, 2022 and November 30, 2021; 45,040,068 and 44,664,371 shares issued and outstanding as of May 31, 2022 and November 30, 2021, respectively | 45 | 45 |
Additional paid-in capital | 578,605 | 563,757 |
Accumulated other comprehensive loss | (3,085) | (608) |
Accumulated deficit | (308,826) | (220,892) |
Total stockholdersʼ equity | 266,739 | 342,302 |
Total liabilities and stockholdersʼ equity | $ 394,310 | $ 476,771 |